MDxHealth financials
MDxHealth
549300J3MG9F9B5FY646 | Line item | 2022 | 2021 |
|---|---|---|
| Income statement | ||
| Revenue | $37.1M | $22.2M |
| Cost of sales | $17.8M | $11.7M |
| Gross profit | $19.2M | $10.6M |
| Operating profit (EBIT) | -$37.9M | -$26.8M |
| Finance costs | $6.1M | $2.2M |
| Profit before tax | -$44.0M | -$29.0M |
| Income tax expense | $0 | $0 |
| Profit for the year | -$44.0M | -$29.0M |
| Total comprehensive income | -$43.5M | -$28.7M |
| Per share | ||
| Basic EPS | $-0.28 | $-0.24 |
| Free cash flow / share | $-0.23 | $-0.19 |
| Cash flow statement | ||
| Net cash from operating activities | -$34.1M | -$22.5M |
| Net cash from investing activities | -$29.2M | -$896.0K |
| Purchase of PP&E (capex) | $2.8M | $896.0K |
| Purchase of intangibles | $1.4M | $0 |
| Net cash from financing activities | $20.8M | $66.5M |
| Proceeds from borrowings | $34.3M | $0 |
| Repayments of borrowings | $10.8M | $0 |
| Lease liability payments | $1.4M | $1.1M |
| Net change in cash | -$42.4M | $43.1M |
| Balance sheet | ||
| Total assets | $119.1M | $75.1M |
| Non-current assets | $90.0M | $8.5M |
| Property, plant & equipment | $3.8M | $1.7M |
| Right-of-use assets | $4.1M | $3.3M |
| Intangible assets & goodwill | $35.9M | $0 |
| Current assets | $29.1M | $66.6M |
| Cash & equivalents | $15.5M | $58.5M |
| Total equity | $9.3M | $46.9M |
| Non-current liabilities | $91.5M | $11.7M |
| Long-term borrowings | $34.9M | $7.7M |
| Lease liabilities (non-current) | $3.1M | $2.6M |
| Current liabilities | $18.3M | $16.4M |
| Short-term borrowings | $616.0K | $4.4M |
| Lease liabilities (current) | $1.2M | $840.0K |
| Derived metrics | ||
| Free cash flow | -$36.9M | -$23.4M |
| Operating margin | -102.3% | -120.7% |
| Net margin | -118.9% | -130.4% |
| Return on equity | -472.8% | -61.8% |
| Cash conversion ratio | 0.77× | 0.78× |
| Capex coverage | -12.23× | -25.17× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -$416.0K | $413.0K |
| Adjustments For Decrease Increase In Trade Account Receivable | -$5.1M | -$1.4M |
| Adjustments For Depreciation and Amortisation Expense | $4.9M | $3.0M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | $44.0K | $0 |
| Adjustments For Increase Decrease In Trade and Other Payables | $4.0M | $1.3M |
| Adjustments For Sharebased Payments | $867.0K | $1.2M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -$32.6M | -$22.9M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | $25.0M | $0 |
| Consideration Paid Received | -$125.0K | -$11.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -$555.0K | -$520.0K |
| Equity and Liabilities | $119.1M | $75.1M |
| General and Administrative Expense | $23.5M | $14.1M |
| Increase Decrease Through Sharebased Payment Transactions | $867.0K | $1.2M |
| Intangible Assets Other Than Goodwill | $46.2M | $3.4M |
| Interest Paid Classified As Financing Activities | $1.4M | $1.0M |
| Inventories Total | $2.3M | $1.9M |
| Issue of Equity | $5.0M | $75.3M |
| Issued Capital | $133.5M | $128.5M |
| Liabilities | $109.8M | $28.2M |
| Licence Fee Income | $25.0K | $250.0K |
| Other Adjustments For Noncash Items | -$473.0K | -$325.0K |
| Other Comprehensive Income | $593.0K | $264.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation Other Than Translation of Foreign Operations | $593.0K | $264.0K |
| Other Current Assets | $2.0M | $1.6M |
| Other Current Financial Liabilities | $2.3M | $961.0K |
| Other Current Liabilities | $4.0M | $2.7M |
| Other Noncurrent Financial Liabilities | $53.5M | $1.5M |
| Other Operating Income Expense | $559.0K | $1.2M |
| Proceeds From Issuing Shares | $0 | $68.6M |
| Research and Development Expense | $7.6M | $6.7M |
| Reserve of Exchange Differences On Translation | -$444.0K | -$1.0M |
| Reserve of Sharebased Payments | $11.5M | $10.6M |
| Retained Earnings | -$288.3M | -$244.3M |
| Revenue From Rendering of Services | $37.0M | $21.9M |
| Revenue From Royalties | $64.0K | $52.0K |
| Selling Expense | $26.6M | $17.7M |
| Share Issue Related Cost | — | $6.8M |
| Share Premium | $153.2M | $153.2M |
| Trade and Other Payables To Trade Suppliers | $10.2M | $7.5M |
| Trade Receivables | $9.4M | $4.6M |
Every line item above is a fact tagged in MDxHealth's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.